Key facts
- It has raised $54.0M; the latest was Buyout/LBO in Nov 2024.
- Notable investors include Lifecore Partners, Lotte Holdings (Japan).
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Omicinsight
- ·The full record, as it builds
Funding rounds
No funding rounds for Omicinsight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Omicinsight
Developer of a single-cell analysis platform designed to deliver molecular insights for biomedical research. The company's platform offers single-molecule sensitivity, resolution imaging, customizable analysis pipelines, and AI-driven data interpretation, enabling researchers, laboratories, and biotechnology organizations to uncover precise cellular insights and accelerate discoveries in medicine and life sciences.
- Sector
- Healthcare
- HQ
- Santa Clara, CA, United States
- Founded
- 2024
- Employees
- 9
- Website
- omicinsight.com/
- Ownership
- Privately Held (backing)
Omicinsight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Omicinsight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Omicinsight in its N-PORT filings yet. We sweep new filings monthly.